Survival benefit of cetuximab for metastatic colorectal cancer
19. 04. 2011 | ecancer.org
Final overall survival improvement of 3.5 months compared with standard chemotherapy − updated analysis from pivotal CRYSTAL trial published in the Journal of Clinical Oncology shows KRAS is the only validated biomarker which is predictive for the efficacy of Erbitux.
Image credit: depositphotos.com
An updated analysis of the Phase III CRYSTALa study has been published in the latest edition of the Journal of Clinical Oncology. The analysis included the evaluation of overall survival (OS) according to KRAS mutation status in patients with metastatic colorectal cancer (mCRC), and found that the addition of Erbitux (cetuximab) to standard chemotherapy (FOLFIRI) in patients with KRAS wild-type disease resulted in a significant improvement in OS of 3.5 months, compared with FOLFIRI alone [1]. CRYSTAL is the only trial to date [2] to demonstrate a significant overall survival benefit of a targeted therapy in combination with current standard chemotherapy (FOLFIRI) in 1st line treatment of mCRC.
Read the whole article at ecancer.org
Reference
- Cutsem EV, Köhne CH et al. Cetuximab plus irinotecan, fluorouracil, and leucovorin as first-line treatment for metastatic colorectal cancer: updated analysis of overall survival according to tumor KRAS and BRAF mutation status. Journal of Clinical Oncology 2011. doi: 10.1200/JCO.2010.33.5091
- Winer E, Gralow J, et al. Clinical cancer advances 2008: major research advances in cancer treatment, prevention, and screening--a report from the American Society of Clinical Oncology. Journal of Clinical Oncology 2009. doi: 10.1200/JCO.2008.21.2134
Keywords: cetuximab, advanced bowel cancer
